You are here: Industry Insights > Alexion

News List

NICE recommends Alexion’s PNH treatment Ultomiris pharmatimes
April 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Alexion’s C5 complement inhibitor Ultomiris for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
AstraZeneca Receives US Clearance of Proposed Acquisition of Alexion americanpharmaceuticalreview
April 19, 2021
AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc (Alexion) has achieved an important step toward completion, having cleared US Federal Trade Commission review.
Biopharma Manufacturer HPNE Continues Expansion contractpharma
February 05, 2021
High Purity New England (HPNE), a biopharma solutions manufacturer and distributor, has acquired their third facility, expanding their total footprint to include more than 100,000 square feet under roof.
AstraZeneca to acquire Alexion expresspharma
December 14, 2020
AstraZeneca and Alexion Pharmaceuticals have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Alexion to buy Portola Pharmaceuticals for $1.41bn pharmaceutical-technology
May 07, 2020
Alexion Pharmaceuticals has signed a definitive agreement to acquire Portola Pharmaceuticals for a total consideration of $1.41bn, or $18 per share.
Alexion Announces CFO Succession americanpharmaceuticalreview
September 19, 2019
Alexion Pharmaceuticals announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year. He will be succeeded by Aradhana Sarin, M.D. ...
Is a Soliris patent review that big a threat to Alexion? Analysts are split fiercepharma
September 08, 2019
Things haven’t gone Alexion’s way lately: After investors cheered the possibility of an Amgen merger, the hoped-for partner advanced its Soliris patent challenge.
Alexion Receives Positive CHMP Opinion for SOLIRIS americanpharmaceuticalreview
July 29, 2019
Alexion Pharmaceuticals announced the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to extend the current marketing authorization of SOLIRIS® (eculizumab) to ...
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price? fiercepharma
July 28, 2019
In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going so well, why are investors so wary?
Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan fiercepharma
July 04, 2019
In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added another indication this week that could rake in $1 billion

Previous page 1 2 3 4 5 Next page